<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2059">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134363</url>
  </required_header>
  <id_info>
    <org_study_id>MD-208-2021</org_study_id>
    <nct_id>NCT05134363</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.</brief_title>
  <official_title>Dexmedetomidine for Prophylaxis Against Postoperative Nausea and Vomiting in Highly Susceptible Patients: a Randomised Controlled Comparison of Two Bolus Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare between two bolus doses of dexmedetomidine in preventing PONV in&#xD;
      highly susceptible patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Being A challenging complaint, many studies tried to find an effective preventive strategies&#xD;
      for PONV. In this study protocol the investigators aim to compare between 0.5 mic/kg and 0.75&#xD;
      mic/kg bolus doses of dexmedetomidine when given toward the end of head and neck surgeries in&#xD;
      highly susceptible patients with a controlled group receiving ondansetron.&#xD;
&#xD;
      The primary outcome is the 1st 24 hours incidence of PONV&#xD;
&#xD;
      Other outcomes include:&#xD;
&#xD;
        -  Time to 1st call for rescue antiemetic and the total amount of antiemetics&#xD;
&#xD;
        -  Number of PONV attacks&#xD;
&#xD;
        -  Post operative pain score with visual analogous scale (VAS) and time to 1st call for&#xD;
           rescue analgesia&#xD;
&#xD;
        -  Sedation Score using Observer's Assessment of Alertness and sedation (OAA/S)&#xD;
&#xD;
        -  Patient satisfaction&#xD;
&#xD;
        -  Vital signs in the 1st 24 hours&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>comparative study between two doses and a 3rd control group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of PONV in the 1st 24 hours postoperatively</measure>
    <time_frame>The first 24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>The overall incidence of nausea and vomiting in the 1st 24 hours following Head and neck surgeries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of PONV attacks</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>Number of PONV attacks in the 1st 24 hours following Head and neck surgeries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score postoperatively.</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>Pain assessement using visual analogous scale score (0-10) with 10 denoting the worst pain expressed and zero= no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation score</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>using Observer's assessment of ALERTNESS and Sedation (1-5)with 1 = unconscious and 5= Alert</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>The patient completes a simple questionnaire with 0= very satisfied 1 = satisfied 2= not satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>Mean arterial blood pressure (MAP) in the 1st 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>Pulse rate in the 1st 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to 1st call for rescue antiemetic</measure>
    <time_frame>In the 1st 24 hours</time_frame>
    <description>time to 1st call for rescue antiemetic and the severity of nausea ( using the 11 verbal 11-point rating scale 0= no nausea 10= the worst nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of nausea.</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>the severity of nausea ( using the 11 verbal 11-point rating scale 0= no nausea 10= the worst nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of morphine consumption</measure>
    <time_frame>The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )</time_frame>
    <description>morphine consumed in thw 1st 24 hours in milligrams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to 1st call for rescue analgesia</measure>
    <time_frame>In the first 24 hours</time_frame>
    <description>time to 1st call for rescure analgesic medication in the 1st 24 hours postoperatively</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <condition>Head and Neck Surgeries</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.5 mic/kg bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>selective alpha 2 adrenergic receptor agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine 0.75 mic/kg bllus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>selective alpha 2 adrenergic receptor agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receving equal volume of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride 0.5 mic/kg bolus</intervention_name>
    <description>comparison between two bolus doses of dexmedetomidine with a placebo group</description>
    <arm_group_label>Dexmedetomidine 0.5 mic/kg bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride 0.75 mic/kg bolus</intervention_name>
    <description>comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.</description>
    <arm_group_label>dexmedetomidine 0.75 mic/kg bllus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>equal volume of normal saline</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 2 risk factors for PONV ( female, non-smoking, postoperative opioids,&#xD;
             history of motion sickness or PONV )&#xD;
&#xD;
          -  Head and neck surgeries in adults&#xD;
&#xD;
          -  ASA ( I , II )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on ( steroids , antiemetics or any drug caude emesis )&#xD;
&#xD;
          -  Any active cardiac condition at the time of the surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700.</citation>
    <PMID>10485781</PMID>
  </reference>
  <results_reference>
    <citation>Kim SH, Oh YJ, Park BW, Sim J, Choi YS. Effects of single-dose dexmedetomidine on the quality of recovery after modified radical mastectomy: a randomised controlled trial. Minerva Anestesiol. 2013 Nov;79(11):1248-58. Epub 2013 May 23.</citation>
    <PMID>23698545</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amr Raafat Mahmoud Seif</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>PONV</keyword>
  <keyword>ondansetron</keyword>
  <keyword>post operative</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

